In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

For some people, diet, and exercise are not enough to lose weight and keep it off. This is where weight loss medication, ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

Viking Therapeutics Inc.’s stock was up up as much as 3.8% early Friday as excitement continued to build about data on the ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...

The acquisition, announced in February, underscores Novo Nordisk’s push to boost output of its popular obesity drug Wegovy.

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, designed to ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?

Maryland’s policymakers should expand Medicaid coverage to include weight loss medications, writes Michelle Rogers.